Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- BclxL antiapoptotic Bcl2 Bclx BH 1 2 3 4 proapoptotic embryo-genesis MXL 90 AXL 42 S62 A KB3 Bcl-X bcl-xL BCL-XL/S bcl-xS BCL2L BCLX BCLXL BCLXS PPP1R52
- Product Overview:
Bcl-xL is an anti-apoptotic member of the Bcl-2 family of proteins and is the long isoform of the apoptosis regulator Bcl-x formed by alternative splicing.{55180} Bcl-xL is composed of a C-terminal helix that acts as a membrane anchor and four highly conserved Bcl-2 homology (BH) domains.{16714} The BH1, BH2, and BH3 domains form a hydrophobic cleft that facilitates Bcl-xL heterodimerization with the pro-apoptotic proteins Bax and Bak, resulting in their inhibition, whereas the BH4 domain regulates intracellular calcium levels.{16714,55181} Bcl-xL is highly expressed during embryogenesis and neuron and lymphocyte development and is primarily localized to the mitochondrial outer membrane.{55182} It inhibits the intrinsic apoptotic pathway by inhibiting Bax- or Bak-induced pore formation in the outer mitochondrial membrane, maintaining the mitochondrial membrane potential, and preventing the release of cytochrome c into the cytosol and the induction of apoptosis.{55183} Increased Bcl-xL levels promote cell migration, invasion, and capillary-like structure formation in MXL90 melanoma and AXL42 glioblastoma cancer cells, which endogenously express high levels of Bcl-xL.{55184} Mutation of serine 62 (S62A) in Bcl-xL mimics its phosphorylation and abolishes apoptosis induced by the microtubule inhibitor vinblastine (Item No. 11762) in KB-3 cells.{55185} Cayman’s Bcl-xL (human, recombinant) protein can be used for binding assay applications. This protein consists of 212 amino acids and has a calculated molecular weight of 25.2 kDa. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 32 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.